Serial No.: 09/664,958

Filed: September 18, 2000

Page 3

## REMARKS

Applicants note that the subject application contains sequence Figure 31A-D that are encompassed by the in definitions for amino acid sequences set forth in 37 C.F.R. 1.821(a)(2) but were not included in the Sequence Listing filed June 4, 2002. Accordingly, in order to comply with the requirements of 37 C.F.R. 1.821 through 1.825, applicants attach hereto a corrected Sequence Listing which includes the amino acid sequences disclosed in Figure 31A-D. Applicants have also amended the specification as indicated hereinabove to identify the SEQ ID NOs. of the amino acid sequences disclosed in Figure Applicants maintain that these amendments are raise no Accordingly, applicants respectfully issue of new matter. request that the Examiner enter this Amendment.

## Sequence Listing

Applicants note that the Sequence Listing filed June 4, 2002 in the subject application inadvertently contains the following discrepancies: (1) SEQ ID NO:17 should correspond to the nucleotide sequence shown in Figure 38 but is missing nucleotides 781-840 of the Figure 38 sequence; (2) SEQ ID NO:23 should correspond to the nucleotide sequence in Figure 41A but is missing the "c" at position 429; the "a" at position 536; and nucleotides 961-1020 as shown in Figure 41A; and (3) the peptide sequences shown in Figure 31A-D are not included in the Sequence Listing.

Applicants therefore attach hereto as **Exhibit A** a paper copy of a corrected Sequence Listing in compliance with the requirements of 37 C.F.R. §1.823. In this corrected Sequence Listing, the sequences of SEQ ID NOs. 17 and 23 have been changed to correspond to the sequences shown in Figures 38 and 41A,

Serial No.: 09/664,958

Filed: September 18, 2000

Page 4

respectively, and the peptide sequences shown in Figure 31A-D have been added. Applicants note that thirty-three peptide sequences are included in Figure 31A-D, but eight of these are repeated and therefore only SEQ ID NOs. corresponding to the twenty-five unique peptide sequences are included in the Sequence Listing.

Applicants also attach hereto as **Exhibit B** a diskette containing a computer readable form (CRF) copy of the Sequence Listing in compliance with 37 C.F.R. §1.824. Further, applicants attach hereto as **Exhibit C** a Statement in Accordance with 37 C.F.R. §1.821(f), certifying that the contents of the enclosed paper copy of the Sequence Listing and the CRF copy are the same and include no new matter.

Serial No.: 09/664,958

Filed: September 18, 2000

Page 5

## Supplemental Information Disclosure Statement

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(b)(4) to supplement the Information Disclosure Statements filed July 30, 2003, September 19, 2003, November 12, 2003 and June 28, 2005 in connection with the above-identified application.

In accordance with their duty of disclosure under 37 C.F.R. \$1.56, applicants direct the Examiner's attention to the following reference which is listed on the attached Form PTO-1449 (Exhibit D), and attached hereto as Exhibit 1:

1. PCT International Publication No. WO 00/69898, published November 23, 2000 (Exhibit 1).

The Examiner is respectfully requested to make this reference of record in the present application by initialing and returning a copy of the enclosed Form PTO-1449.

Applicants note that the above-listed reference was previously cited in a Supplementary Partial European Search Report issued July 14, 2005 in connection with European Patent Application No. 01973176.9, a foreign counterpart of the subject application. A copy of the July 14, 2005 Supplementary Partial European Search Report is attached hereto as **Exhibit E**.

Applicants also note that the four references cited in the July 14, 2005 European Search Report (Exhibit E), other than the above-listed WO 00/69898, are not listed above because these references were previously made of record in the subject application. That is, WO 99/49279 was cited to the Examiner in the Information Disclosure Statement filed July 30, 2003, and EP 1006184, Kirman et al. (2002) and Kalantarov et al. (2002) were

Serial No.: 09/664,958

Filed: September 18, 2000

Page 6

cited in the Information Disclosure Statement filed June 28, 2005.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Pursuant to 37 C.F.R. §1.97(b)(4), no fee is deemed necessary in connection with the filing of this Amendment and Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

ſ

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with in an envelope addressed to:
Mail Stop Ameridment, Commissioner for
Patents, P.O Box 1450, Alexandria'
VA 22313-1450 sufficient postage as first class mail

Morrison

Reg. No. 37,399

John P. White Registration No. 28,678 Alan J. Morrison Registration No. 37,399 Attorneys for Applicant(s) Cooper & Dunham, LLP 1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400